Trial record 19 of 60 for:
"Common Cold"
Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold
This study has been completed.
Sponsor:
Bayer
Information provided by:
Bayer
ClinicalTrials.gov Identifier:
NCT01361399
First received: May 25, 2011
Last updated: NA
Last verified: May 2011
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to investigate the analgesic efficacy of a single dose of a fixed combination of 500 mg Aspirin (Acetylsalicylic Acid) and 4 mg Lidocaine in adult patients with sore throat associated with a common cold in comparison to a single treatment with 500 mg Aspirin or 4 mg Lidocaine alone as well a Placebo (treatment without any active ingredient). The combination of Aspirin and Lidocaine in a single lozenge is expected to provide relief from sore throat pain by sequential action. A very fast inset of action will be achieved by the locally acting Lidocaine and a long duration of action will be achieved by the systemically acting Aspirin.
| Condition | Intervention | Phase |
|---|---|---|
|
Common Cold Pharyngitis Tonsillitis |
Drug: Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain Drug: Acetylsalicylic Acid (Aspirin, BAYE4465) Drug: Lidocain Drug: Placebo |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A 4-arm, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Single Dose, Parallel Group Study Comparing Efficacy and Safety of a Fixed Combination of 500 mg Acetylsalicylic Acid + 4 mg Lidocaine With 500 mg Acetylsalicylic Acid and 4 mg Lidocaine Monotherapy as Well as Placebo in Adult Patients With Sore Throat Associated With a Common Cold. |
Resource links provided by NLM:
Further study details as provided by Bayer:
Primary Outcome Measures:
- Sum of pain intensity differences SPID [ Time Frame: 120 minutes ] [ Designated as safety issue: No ]
- Pain intensity difference to baseline (PID12 min) [ Time Frame: 12 minutes ] [ Designated as safety issue: No ]
- Pain intensity difference to baseline (PID120 min) [ Time Frame: 120 minutes ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Pain intensity difference to baseline (PID) [ Time Frame: 3, 6, 12, 18, 24, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 210 and 240 minutes post dose ] [ Designated as safety issue: No ]
- Total pain relief to baseline (TOTPAR) [ Time Frame: 3, 6, 12, 18, 24, 30, 40, 50, 60, 75, 90, 105, 120, 150, 180, 210 and 240 minutes post dose ] [ Designated as safety issue: No ]
- Symptoms of common cold (headache, sinus pressure/pain, feverish discomfort, muscle aches and pain) [ Time Frame: 60, 120, 180, and 240 minutes post dose ] [ Designated as safety issue: No ]
- Overall assessment of treatment [ Time Frame: 240 minutes ] [ Designated as safety issue: No ]
- Assessment of safety and tolerability [ Time Frame: 240 minutes ] [ Designated as safety issue: Yes ]
| Enrollment: | 1088 |
| Study Start Date: | November 2004 |
| Study Completion Date: | May 2005 |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Arm 1 |
Drug: Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain
Single oral application of a fixed combination of Aspirin and Lidocain (as one lozenge)
|
| Active Comparator: Arm 2 |
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
Single oral application of Aspirin (as lozenge)
|
| Active Comparator: Arm 3 |
Drug: Lidocain
Single oral application of Lidocain (as lozenge)
|
| Placebo Comparator: Arm 4 |
Drug: Placebo
Single oral application of Placebo (as lozenge)
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Males and females of at least 18 years of age
- Onset of common cold within the last 3 days (12 to 72 hours)
- History of at least 4 symptoms associated with URTI in the last 24 hours out of runny nose, stuffy nose, sneezing, wet cough, dry cough, sweating, earache, ear fullness, sinus pressure/pain, head heaviness, muscle aches and pains, feverish discomfort, chills, hoarseness, sore throat, scratchy throat and headache as documented in the history of URTI
- Current sore throat confirmed by a score ≥ 6 on a 11-category vertical ordinal scale for sore throat pain
- Findings that confirmed the presence of tonsillopharyngitis
Exclusion Criteria:
- Pregnancy (i.e. positive pregnancy test at baseline)
- Breastfeeding
- History of hypersensitivity (allergic reaction) to ASA or any other NSAID
- History of hypersensitivity (allergic reaction) to lidocaine
- History or acute state of peptic ulceration or gastrointestinal bleeding
- History of bleeding tendency
- History of asthma
- Clinical diagnosis of chickenpox or influenza
- History or presence of severe liver or kidney disease
- Intake of short-acting analgesics (e.g. ASA, paracetamol, ibuprofen, diclofenac) either as a single ingredient or as part of a combination cold product in the last 6 hours, or intake of long-acting analgesics (e.g. naproxen) in the last 12 hours, or intake of any other NSAID in the last 24 hours
- Use of any local or systemic short-acting cough and cold preparation (e.g. decongestant or antihistaminic drug) in the last 12 hours
- Use of any cough or sore throat lozenges/candies or any menthol-containing product (including mentholated tissues) in the last 6 hours
- Current intake or requirement of any prescription medication for the current treatment of acute respiratory tract illness
- Administration of anticoagulants in the last 7 days
- Inability to breathe through the nose or a history of chronic mouth breathing
- Presence of any severe concomitant disease or condition which, in the opinion of the investigator, is a reason for exclusion, e.g. serious cardiovascular diseases (in particular arrhythmias), treatment with antiarrhythmics or methotrexate
Contacts and Locations
More Information
Additional Information:
No publications provided
| Responsible Party: | Therapeutic Area Head, Bayer Consumer Care Inc. |
| ClinicalTrials.gov Identifier: | NCT01361399 History of Changes |
| Other Study ID Numbers: | 11640 |
| Study First Received: | May 25, 2011 |
| Last Updated: | May 25, 2011 |
| Health Authority: | Russia: Federal Agency of Drugs Quality Control Ukraine: Ministry of Health |
Keywords provided by Bayer:
|
Sore Throat |
Additional relevant MeSH terms:
|
Common Cold Pharyngitis Tonsillitis Picornaviridae Infections RNA Virus Infections Virus Diseases Respiratory Tract Infections Respiratory Tract Diseases Pharyngeal Diseases Stomatognathic Diseases Otorhinolaryngologic Diseases Aspirin Lidocaine Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic |
Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Anti-Inflammatory Agents Therapeutic Uses Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Cardiovascular Agents Hematologic Agents Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors |
ClinicalTrials.gov processed this record on June 18, 2013